TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

By sjmartinez • June 30, 2023

Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2023 Jun 30. doi: 10.2217/fon-2023-0188. Epub ahead of print. PMID: 37387213.

Tags: antibody-drug conjugate (ADC), Cedars Sinai DoM, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, HR-positive/HER2-negative, inoperable breast cancer, metastatic breast cancer, Publications, Trophoblast cell surface antigen 2 (TROP2)

Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021

Danpanichkul P, Duangsonk K, Tham EKJ, Tothanarungroj P, Auttapracha T, Prasitsumrit V, Sim B, Tung D, Barba R, Wong RJ, Leggio L, Yang JD, Chen[...]

A Promising Pathway Toward Mitigation and Eradication of Coronary Artery Disease

Karlsberg RP, Cho GW, Aldana-Bitar J. A Promising Pathway Toward Mitigation and Eradication of Coronary Artery Disease. Cardiol Res. 2024 Dec;15(6):415-424. doi: 10.14740/cr1721. Epub 2024[...]

2024 Update of the RECOVER-Adult Long COVID Research Index

Geng LN, Erlandson KM, Hornig M, Letts R, Selvaggi C, Ashktorab H, Atieh O, Bartram L, Brim H, Brosnahan SB, Brown J, Castro M, Charney[...]